Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LINO-1713 in Healthy Korean Female Subjects

NCT05677035 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Contraception

Interventions

DRUG: LINO-1713 1 tablet
DRUG: LINO-1713 once a day for 24 days

Sponsor

Hyundai Pharm